UK-based TechBio company BenevolentAI uses Claude to evaluate datasets, annotate evidence for model fine-tuning, and textualize non-literature data modalities for its models to reason over.

📢We’re pleased to share positive topline data from our Phase 1a clinical study of BEN-8744 in healthy volunteers
📢This is being developed as a potential first-in-class treatment for moderate to severe ulcerative colitis
👉 Read more here benevolent.com/news-and-media…

Today BenevolentAI shares its 2023 Annual Report. Download the report on our website

Last week we presented our preliminary results:
👉 Watch a recording of the analyst briefing lnkd.in/eKNf2KZv

👉 Watch our CEO discuss our 2024 Company outlook lnkd.in/ecZy6Erv

🇪🇸 Hola, we are really excited to be attending Bio-Europe Spring 2024 in Barcelona [18-20 March]

💊 Come find out more about BenevolentAI’s partnerships and collaborations to help unlock biological insights, tackle therapeutic challenges and develop novel drugs for disease.

👉Today BenevolentAI announced its preliminary results for the year ending 31st December 2023. Follow link below for full announcement.
👉At 1pm GMT today we will host a webcast analyst briefing, a recording will be available on our website shortly after.
benevolent.com/investors/repo…

Developing effective new drug treatments depends on building evidence from various data.
What is the most critical data for you to do your job?
Select all that apply:

📢Thanks for including us in this series Singer Capital Markets ! Click here to listen to the brilliant 'AI in Action' podcast featuring our COO and Co-Founder Ivan Griffin

Today we’re announcing Joerg Moeller, an accomplished Pharma R&D leader and champion of the application of AI to drug discovery, as our new CEO
💫Joerg brings a wealth of experience to BenevolentAI following an extensive career in R&D
👇Read more here! benevolent.com/news-and-media…

📢 Our Chair and Acting CEO Francois Nader presented at last week's 42nd Annual J.P.Morgan Healthcare Conference - you can now watch the presentation on our website, visit the link below 👇

benevolent.com/investors/repo…